Furosemide Pharmacodynamics and Pharmacokinetics After Subcutaneous or Oral Administration

Heart Failure Clinical Trial

— FUROPHARM-HF  

Official title:

A Single Center, Randomized, Open-label, Cross-over Exploratory Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response to a Subcutaneous Administration or Oral Administration of Furosemide in Subjects With Heart Failure Presenting With Chronic Fluid Overload

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02350725
• Other study ID #: SCP-01-001
• Secondary ID: 2014-002546-49
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: December 2014
• Est. completion date: June 2015

Study information

• Verified date: December 2014
• Source: scPharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this pilot study is to investigate the pharmacodynamic and pharmacokinetic parameters of a novel furosemide formulation administered subcutaneously as compared to oral furosemide.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: June 2015
• Est. primary completion date: June 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Written informed consent obtained before any assessment is performed

• Male and female subjects =18 years of age, with body weight <120 kg and body mass index (BMI) <30 kg/m2

• Female subjects must be at least 2 years post-menopausal

• Participant must have been on oral furosemide (40 mg oid or bid) or therapeutic equivalent (bumetanide 1 mg oid or bid) for a period 90 days before the first dose of study medication

• History of chronic heart failure according to 2012 ESC guidelines with presence of moderate symptoms of chronic fluid overload. Chronic fluid overload is defined as presence of stable signs and symptoms of heart failure and congestion, like dyspnea at mild exertion or minimal exertion, pulmonary congestion and/or peripheral edema at the time of presentation in combination with elevated levels on natriuretic peptides (NT-proBNP > 300 ng/L)

• In the opinion of the investigator, able to participate in the study

Exclusion Criteria:

• Acute Decompensated Heart Failure (ADHF) or recent history of ADHF or significant worsening in their HF symptoms (within prior 2 weeks)

• Contraindication to furosemide

• Systolic BP (SBP) < 90 mm Hg

• Temperature > 38°C (oral or equivalent) or sepsis or active infection requiring i.v. anti-microbial treatment

• Serum sodium < 130 mmol/L and Serum potassium < 3.0 mmol/L

• Current or planned (throughout the completion of study drug infusion) treatment with any i.v. therapies, including inotropic agents, vasopressors, levosimendan, nesiritide or analogues; or mechanical support (intra-aortic balloon pump, endotracheal intubation, mechanical ventilation, or any ventricular assist device)

• History of gastric or intestinal surgery that may affect absorption of oral medication

• Presence or need for urinary catheterization

• Current or planned ultrafiltration, hemofiltration, or dialysis

• Impaired renal function defined as an estimated glomerular filtration rate (eGFR) on admission < 30 mL/min/1.73 m2 will be calculated as per standard at local laboratory

• Administration of intravenous radiographic contrast agent within 72 hours prior to screening or acute contrast-induced nephropathy at the time of screening

• Major surgery within 30 days prior to screening

• Administration of an investigational drug or implantation of investigational device, or participation in another trial, within 30 days before screening

• Inability to follow instructions or comply with procedures

• Any surgical or medical condition which in the opinion of the investigator may interfere with participation in the study or which may affect the outcome of the study

Related Conditions & MeSH terms

• Heart Failure

Intervention

Drug:
• Furosemide injection solution for subcutaneous administration (80 mg)

• Oral Furosemide tablets (80 mg)

Locations

Country	Name	City	State
Netherlands	University Medical Center Groningen	Groningen

Sponsors (1)

Lead Sponsor	Collaborator
scPharmaceuticals, Inc.

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Diuresis and natriuresis	Statistical summaries with a graphical presentation will show mean and individual diuresis and natriuresis time profiles such as time to first void, volume of first void, diuresis and natriuresis measured at 60 minute intervals up to 480 minutes following furosemide injection solution for subcutaneous administration or oral tablets. The diuretic response will be compared between therapies using t-tests or Wilcoxon test.	8 hours
Secondary	Body Water Content	The correlation (Pearson coefficient) between bioimpedance (body water content) and diuresis will be investigated including bioimpedance measurement of fluid overload as a predictor diuretic response.	8 hours
Secondary	Pharmacokinetic profiles	A graphical presentation showing mean and individual plasma furosemide concentration-time profiles for comparison between subcutaneous or oral administration. Plasma furosemide concentration-time data will be analyzed using a non-compartmental method and population PK approach (non-linear mixed-effect model). Furosemide concentrations will be summarized using descriptive statistics (including N, mean, standard deviation (SD), coefficient of variation (CV%), median, minimum and maximum) for each treatment.	8 hours
Secondary	Cardiac Markers (NTpro-BNP, hs-Trop T, galectin-3)	Correlation methods to investigate interaction between cardiac makers (NTpro-BNP, hs-Trop T, galectin-3) and pharmacodynamic parameters (diuresis and natriuresis).	8 hours
Secondary	Dypsnea Scores on Visual Analog Scale and Likert Scale	Dyspnea score (Dyspnea Visual Analog Scale and Likert Scale), the New York Heart Association (NYHA) Functional Classification and thirst distress and grading assessments by subjects in response to subcutaneous or oral administration.	8 hours
Secondary	Injection site reaction on Draize Scale and Visual Analog Pain Scale	Visual inspection of injection site, 5-point Draize Scale and Visual Analog pain assessment recorded during subcutaneous administration.	8 hours

External Links

•   Subcutaneous Furosemide in Heart Failure: Pharmacokinetic Characteristics of a Newly Buffered Solution